MG301 · ALXN1720-MG-301
Public neurological clinical research study information. Check the current recruitment status in the live Wix study record.
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel, Multicenter Study to Evaluate the Safety and Efficacy of ALXN1720 in Adults with Generalized Myasthenia Gravis. EudraCT 2022-000460-21
Sponsor: ALEXION
Phase: III
Area: Neuromuscular disorders